The role of empagliflozin in the management of type 2 diabetes by patient profile

References

• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care201538114014925538310
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• CryerPEDavisSNShamoonHHypoglycemia in diabetesDiabetes Care20032661902191212766131
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBAmerican Diabetes AssociationEuropean Association for the Study of DiabetesMedical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia2009521173018941734
   PubMed Web of Science ®Google Scholar
• PhungOJSobierajDMEngelSSRajpathakSNEarly combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysisDiabetes Obes Metab201416541041724205921
   PubMed Web of Science ®Google Scholar
• KovacsCSSeshiahVSwallowREmpagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trialDiabetes Obes Metab201416214715823906415
   PubMed Web of Science ®Google Scholar
• HäringHUMerkerLSeewaldt-BeckerEEMPA-REG METSU Trial InvestigatorsEmpagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialDiabetes Care201336113396340423963895
   PubMed Web of Science ®Google Scholar
• NelsonJMDufrauxKCookPFThe relationship between glycemic control and falls in older adultsJ Am Geriatr Soc200755122041204417971138
   PubMed Web of Science ®Google Scholar
• WrightEMHirayamaBALooDFActive sugar transport in health and diseaseJ Intern Med20072611324317222166
   PubMed Web of Science ®Google Scholar
• VasilakouDKaragiannisTAthanasiadouESodium–glucose cotransporter 2 inhibitors for type 2 diabetes a systematic review and meta-analysisAnn Intern Med2013159426227424026259
   PubMed Web of Science ®Google Scholar
• RosenstockJSemanLJJelaskaAEfficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemiaDiabetes Obes Metab201315121154116023906374
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationFDA approves Jardiance to treat type 2 diabetes [press release]Silver Spring, MDUS Food and Drug Administration201481 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htmAccessed February 25, 2015
   Google Scholar
• Jardiance^® (empagliflozin) [prescribing information]IngelheimLicensed from: Boehringer Ingelheim International GmbH2014
   Google Scholar
• GremplerRThomasLEckhardtMEmpagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitorsDiabetes Obes Metab2012141839021985634
   PubMed Web of Science ®Google Scholar
• KomoroskiBVachharajaniNBoultonDEmpagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjectsClin Pharmacol Drug Dev201322152161
   PubMed Web of Science ®Google Scholar
• SarashinaAKoiwaiKSemanLJSafety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjectsDrug Metab Pharmacokinet201328321321923149871
   PubMed Web of Science ®Google Scholar
• HeiseTSeewaldt-BeckerEMachaSSafety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetesDiabetes Obes Metab201315761362123356556
   PubMed Web of Science ®Google Scholar
• HeiseTSemanLMachaSSafety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitusDiabetes Ther20134233134523838841
   PubMed Web of Science ®Google Scholar
• BrandTMachaSMattheusMPinnettiSWoerleHJPharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteersAdv Ther2012291088989923054692
   PubMed Web of Science ®Google Scholar
• FriedrichCMetzmannKRosePMattheusMPinnettiSWoerleHJA randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteersClin Ther2013351A33A4223328275
   PubMed Web of Science ®Google Scholar
• ScottLJEmpagliflozin: a review of its use in patients with type 2 diabetes mellitus (vol 74, pg 1769, 2014)Drugs201575114114125428712
   PubMed Web of Science ®Google Scholar
• KadowakiTHanedaMInagakiNEmpagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trialAdv Ther201431662163824958326
   PubMed Web of Science ®Google Scholar
• WoerleHJKadowakiTHanedaMSafety and efficacy of empagliflozin monotherapy in a 52-week study in Japanese patients with type 2 diabetes mellitusPoster No. 930 presented at: 49th Annual Meeting of the European Association for the Study of DiabetesSeptember 23–27 2013Barcelona
   Google Scholar
• FerranniniESemanLSeewaldt-BeckerEHantelSPinnettiSWoerleHJA phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetesDiabetes Obes Metab201315872172823398530
   PubMed Web of Science ®Google Scholar
• RodenMWengJEilbrachtJEMPA-REG MONO Trial InvestigatorsEmpagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialLancet Diabetes Endocrinol20131320821924622369
   PubMed Web of Science ®Google Scholar
• NishimuraRTanakaYKoiwaiKEffect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week studyCardiovasc Diabetol20151411125633683
   PubMed Web of Science ®Google Scholar
• HaringHUMerkerLSeewaldt-BeckerEEmpagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialDiabetes Care20143761650165924722494
   PubMed Web of Science ®Google Scholar
• FerranniniEBerkAHantelSLong-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetesDiabetes Care201336124015402124186878
   PubMed Web of Science ®Google Scholar
• RidderstråleMSvaerdRZellerCEmpagliflozin (EMPA) for ≥76 weeks as add-on to metformin plus sulfonylurea (SU) in patients with type 2 diabetes (T2DM)Diabetes201463suppl 1A280 abstract no.1077-P
   Google Scholar
• KovacsCSSeshiahVMerkerLEmpagliflozin (EMPA) for ≥76 weeks as add-on to pioglitazone with or without metformin in patients with type 2 diabetes (T2DM)Diabetes201463suppl 1A273 abstract no.1055-P
   Google Scholar
• RosenstockJJelaskaAWangFKimGBroedlUCWoerleHJEmpagliflozin as add-on to basal insulin for 78 weeks improves glycaemic control with weight loss in insulin-treated type 2 diabetes mellitusDiabetologia201356S372S372
   Web of Science ®Google Scholar
• RosenstockJJelaskaAFrappinGEMPA-REG MDI Trial InvestigatorsImproved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetesDiabetes Care20143771815182324929430
   PubMed Web of Science ®Google Scholar
• HachTGerichJSalsaliAEmpagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes: pooled data from four pivotal phase III trialsPoster No: 943 presented at: the European Association for the Study of Diabetes (EASD)September 23–27 2013Barcelona
   Google Scholar
• DaileyGEmpagliflozin for the treatment of type 2 diabetes mellitus: an overview of safety and efficacy based on phase 3 trialsJ Diabetes Epub2015211
   PubMedGoogle Scholar
• BarnettAHMithalAManassieJEMPA-REG RENAL Trial InvestigatorsEfficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trialLancet Diabetes Endocrinol20142536938424795251
   PubMed Web of Science ®Google Scholar
• MachaSRosePMattheusMPharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairmentDiabetes Obes Metab201416211812323859534
   PubMed Web of Science ®Google Scholar
• TikkanenINarkoKZellerCEMPA-REG BP InvestigatorsEmpagliflozin reduces blood pressure in patients with type 2 diabetes and hypertensionDiabetes Care201538342042825271206
   PubMed Web of Science ®Google Scholar
• LiakosAKaragiannisTAthanasiadouEEfficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysisDiabetes Obes Metab2014161098499324766495
   PubMed Web of Science ®Google Scholar
• ZinmanBInzucchiSELachinJMRationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)Cardiovasc Diabetol20141310224943000
   PubMed Web of Science ®Google Scholar
• StenlöfKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab201315437238223279307
   PubMed Web of Science ®Google Scholar
• KanaiYLeeWSYouGBrownDHedigerMAThe human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucoseJ Clin Invest19949313974048282810
   PubMed Web of Science ®Google Scholar
• HedringtonMSDavisSNIpragliflozin, a sodium–glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetesExpert Opin Drug Metab Toxicol201511461362325643044
   PubMed Web of Science ®Google Scholar
• BaileyCJMorales VillegasECWooVTangWPtaszynskaAListJFEfficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trialDiabet Med201532453154125381876
   PubMed Web of Science ®Google Scholar
• NyirjesyPZhaoYWaysKUsiskinKEvaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitorCurr Med Res Opin20122871173117822632452
   PubMed Web of Science ®Google Scholar
• BaileyCJGrossJLPietersABastienAListJFEffect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialLancet201037597332223223320609968
   PubMed Web of Science ®Google Scholar